<?xml version="1.0" encoding="UTF-8"?>
<ref id="B19-pharmaceutics-10-00039">
 <label>19.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Dorr</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Westby</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Dobbs</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Griffin</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Irvine</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Macartney</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Mori</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Rickett</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Smith-Burchnell</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Napier</surname>
    <given-names>C.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity</article-title>
  <source>Antimicrob. Agents Chemother.</source>
  <year>2005</year>
  <volume>49</volume>
  <fpage>4721</fpage>
  <lpage>4732</lpage>
  <pub-id pub-id-type="doi">10.1128/AAC.49.11.4721-4732.2005</pub-id>
  <?supplied-pmid 16251317?>
  <pub-id pub-id-type="pmid">16251317</pub-id>
 </element-citation>
</ref>
